Javascript must be enabled to continue!
Baclofen therapy for chronic hiccup
View through CrossRef
Chronic hiccup is a rare but potentially severe condition, that can be symptomatic of a variety of diseases, or idiopathic. Many therapeutic interventions have been reported, most often as case reports. Among other drugs, baclofen has been suggested as a therapy for chronic hiccup. In a large series of patients, we have evaluated its therapeutic position. In patients with chronic hiccup, defined as hiccup spell or recurring hiccup attacks lasting more than 7 days, investigation of the upper gastro-oesophageal tract (fibroscopy, manometry, and pH monitoring) was systematically performed. Most patients had tried numerous drugs in the past, without success. Baclofen was used as a first treatment in patients without evidence of any gastro-oesophageal disease (n = 17), and was undertaken only after full treatment of such disease (n = 55) had failed to solve the hiccup problem (n = 20). Baclofen has, therefore, been administered to 37 patients with chronic hiccup (average duration 4.6 yrs). Baclofen produced a long-term complete resolution (18 cases) or a considerable decrease (10 cases) of hiccups in 28 of the 37 patients. There was no significant difference between patients with or without gastro-oesophageal disease. We conclude that so-called idiopathic chronic hiccup often results from gastro-oesophageal abnormalities. Also, if controlled studies confirm our encouraging results, baclofen can be a major element in the treatment of chronic hiccup that is idiopathic, or that cannot be helped by treatment of gastro-oesophageal diseases.
European Respiratory Society (ERS)
Title: Baclofen therapy for chronic hiccup
Description:
Chronic hiccup is a rare but potentially severe condition, that can be symptomatic of a variety of diseases, or idiopathic.
Many therapeutic interventions have been reported, most often as case reports.
Among other drugs, baclofen has been suggested as a therapy for chronic hiccup.
In a large series of patients, we have evaluated its therapeutic position.
In patients with chronic hiccup, defined as hiccup spell or recurring hiccup attacks lasting more than 7 days, investigation of the upper gastro-oesophageal tract (fibroscopy, manometry, and pH monitoring) was systematically performed.
Most patients had tried numerous drugs in the past, without success.
Baclofen was used as a first treatment in patients without evidence of any gastro-oesophageal disease (n = 17), and was undertaken only after full treatment of such disease (n = 55) had failed to solve the hiccup problem (n = 20).
Baclofen has, therefore, been administered to 37 patients with chronic hiccup (average duration 4.
6 yrs).
Baclofen produced a long-term complete resolution (18 cases) or a considerable decrease (10 cases) of hiccups in 28 of the 37 patients.
There was no significant difference between patients with or without gastro-oesophageal disease.
We conclude that so-called idiopathic chronic hiccup often results from gastro-oesophageal abnormalities.
Also, if controlled studies confirm our encouraging results, baclofen can be a major element in the treatment of chronic hiccup that is idiopathic, or that cannot be helped by treatment of gastro-oesophageal diseases.
Related Results
0864 Severe Central Sleep Apnea
0864 Severe Central Sleep Apnea
Abstract
Introduction
Central sleep apnea (CSA) is a rare form of sleep disordered breathing with repeated apneic episodes with ...
Cardiac Arrest: A Rare Complication of Intrathecal Baclofen Withdrawal
Cardiac Arrest: A Rare Complication of Intrathecal Baclofen Withdrawal
Baclofen, a GABA agonist, is used for the management of spasticity. Intrathecal route is indicated in cases of severe spasticity associated with spinal cord injury. Baclofen withdr...
Prepontine placement of an intrathecal baclofen pump catheter for treatment of dystonia
Prepontine placement of an intrathecal baclofen pump catheter for treatment of dystonia
Background:
Cerebral palsy with medically refractory spasticity and dystonia is a condition that often benefits from intrathecal baclofen pump therapy to treat these symptoms. In ...
Baclofen and phaclofen modulate GABA release from slices of rat cerebral cortex and spinal cord but not from retina
Baclofen and phaclofen modulate GABA release from slices of rat cerebral cortex and spinal cord but not from retina
The effects of (−)‐baclofen, muscimol and phaclofen on endogeneous γ‐aminobutyric acid (GABA) release from rat cortical slices, spinal cord slices and entire retinas were studied.T...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Sleep-Related Painful Erections—A Case Series of 24 Patients Regarding Diagnostics and Treatment Options
Sleep-Related Painful Erections—A Case Series of 24 Patients Regarding Diagnostics and Treatment Options
Abstract
Background
Patients with sleep-related painful erections (SRPEs) have deep penile pain during nocturnal erection that w...
Altered Mental Status at High Altitude
Altered Mental Status at High Altitude
Intrathecal baclofen pumps are commonly used in pediatric patients with spastic cerebral palsy. Baclofen binds to γ-aminobutyric acid receptors to inhibit both monosynaptic and pol...
A standardized protocol to reduce pediatric baclofen pump infections: a quality improvement initiative
A standardized protocol to reduce pediatric baclofen pump infections: a quality improvement initiative
OBJECTIVEIntrathecal baclofen pumps are generally placed in children for the treatment of spasticity and dystonia. Use of implants in this pediatric population with comorbidities i...

